Investors & News / Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update Read more about Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors Read more about Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 Read more about Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 Exelixis to Present at the William Blair 44th Annual Growth Stock Conference Read more about Exelixis to Present at the William Blair 44th Annual Growth Stock Conference Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA Read more about Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA Sudan Loganathan, PhD Sudan Loganathan, PhD Stephens Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update Read more about Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update 2023 Annual Report (pdf) Read more about 2023 Annual Report (pdf) Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to Receive Email Alerts Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Submit. Required fields denoted by an asterisk (). Alert type Exelixis SEC Alert Exelixis End-of-Day SEC Alert Exelixis Calendar Alert Exelixis News Alert Exelixis Report Alert Email Leave this field blank Shareholder Tools Information Request Print Page RSS
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update Read more about Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors Read more about Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024 Read more about Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference Read more about Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA Read more about Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May Read more about Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update Read more about Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update